Update shared on 07 Nov 2025
Fair value Increased 13%Narrative Update on Apyx Medical: Analyst Price Target Revision
Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.
What's in the News
- Apyx Medical raised its earnings guidance for 2025, now expecting total revenue between $50.5 million and $52.5 million. This is up from its previous forecast and the 2024 total of $48.1 million (Key Developments).
- The company submitted a new 510(k) notification to the FDA to expand the AYON Body Contouring System's label to include power liposuction. The aim is to establish AYON as the first fully integrated body contouring system (Key Developments).
- Apyx Medical will host an event featuring surgeon Paul Vanek, Jr., MD, to discuss the upcoming commercial launch of the AYON Body Contouring System on October 14, 2025 (Key Developments).
- Stockholders approved an amendment to the company's Certificate of Incorporation at the annual meeting held on August 7, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: Increased from $4.00 to $4.50 per share
- Discount Rate: Slightly decreased from 8.67% to 8.46%
- Revenue Growth: Dropped significantly from 12.11% to 7.49%
- Net Profit Margin: Improved from 12.49% to 13.54%
- Future P/E: Increased from 28.85x to 32.78x
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.